Abstract 1604P
Background
Analysis of the most common prevalent symptoms among patients with advanced cancer diagnosis is needed in order to reach the most appropriate interventions leading to improved quality of life of these patients. The aim of this study is to report on the overall symptom prevalence among patients with advanced cancer diagnosis under palliative care and to analyze the difference of symptom prevalence between elderly (≥ 65 years) and adult (<65 years) patients.
Methods
A retrospective cohort study of 400 patients with advanced cancer who were admitted under palliative care between 1st January 2017 to December 31st, 2021. Data were retrieved from electronic medical records.
Results
Anorexia (91%), fatigue (98%), drowsiness (84%) and pain (83%) were the highest 4 prevalent symptoms for the whole group, followed by depression (76%) and anxiety (72%). Adult patients had significant higher pain (80% versus 76%), depression (83% versus 68%) and anxiety (77% versus 65%), compared to elderly (≥ 65 years) patients. On multivariate analysis, pain only was significantly higher in adult patients (p=0.021). The reported percentage of symptom prevalence for the whole group is higher than that in the literature, indicating late referral to palliative care.
Conclusions
There is a high percentage of symptom prevalence among our patients and a short median overall survival that indicates late referral to palliative care. Adult patients had significantly higher pain, depression, and anxiety compared to elderly patients. An earlier integration of palliative care is recommended in the overall management of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05